Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 3/20 | 0.59 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | CYP1A1 | P04798 | 4/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.58 |
| ▸ | CYP1B1 | Q16678 | 4/20 | 0.55 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | ACHE | P22303 | 2/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | BCHE | P06276 | 1/20 | 0.52 |
| ▸ | GSK3B | P49841 | 1/20 | 0.50 |
| ▸ | CREB1 | P16220 | 1/20 | 0.49 |
| ▸ | AURKA | O14965 | 1/20 | 0.49 |
| ▸ | KDR | P35968 | 1/20 | 0.49 |
| ▸ | FLT3 | P36888 | 1/20 | 0.49 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24514601 | 0.91 | ABCB1 (0.73) | ABCB1ABCG2MEN1TP53MDM2 | |
| SCHEMBL1976409 | 0.90 | CYP1A1 (0.59) | ABCB1ABCG2MEN1TP53MDM2 | |
| SCHEMBL24514598 | 0.90 | ABCB1 (0.68) | ABCB1ABCG2MEN1TP53MDM2 | |
| SCHEMBL8068919 | 0.89 | ABCB1 (0.73) | ABCB1ABCG2MEN1TP53MDM2 | |
| SCHEMBL7156543 | 0.89 | ABCB1 (0.69) | ABCB1ABCG2MEN1TP53MDM2 | |
| SCHEMBL1423904 | 0.88 | MEN1 (0.52) | ABCB1ABCG2MEN1TP53MDM2 | |
| SCHEMBL8052863 | 0.88 | ABCB1 (0.64) | ABCB1ABCG2MEN1TP53MDM2 | |
| SCHEMBL24514602 | 0.87 | CYP1A1 (0.75) | ABCB1ABCG2MEN1TP53MDM2 | |
| SCHEMBL4649969 | 0.87 | ABCB1 (0.73) | ABCB1ABCG2MEN1TP53MDM2 | |
| SCHEMBL8052929 | 0.87 | ABCB1 (0.69) | ABCB1ABCG2MEN1TP53MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110144194-A1 | CHROMENONE DERIVATIVES USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | AXOGLIA THERAPEUTICS (LU) | 2011-06-16 | — | — | US | disclosed |
| EP-2112145-A1 | Chromenone derivatives useful for the treatment of neurodegenerative diseases | AxoGlia Therapeutics S.A. (LU) | 2009-10-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144194-A1 | CHROMENONE DERIVATIVES USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | PARK7, CDR2, SNCA | ABCB1 2178/4885ABCG2 1767/4885MEN1 1507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.